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Abstract: Acrylamide is widely used worldwide in industry and it can also be produced by 
the cooking and processing of foods. It is harmful to human beings, and human brain CK 
(HBCK) has been proposed to be one of the important targets of acrylamide. In this 
research, we studied the effects of acrylamide on HBCK activity, structure and the 
potential binding sites. Compared to CKs from rabbit, HBCK was fully inactivated at 
several-fold lower concentrations of acrylamide, and exhibited distinct properties upon 
acrylamide-induced inactivation and structural changes. The binding sites of acrylamide 
were located at the cleft between the N- and C-terminal domains of CK, and Glu232 was 
one of the key binding residues. The effects of acrylamide on CK were proposed to be 
isoenzyme- and species-specific, and the underlying molecular mechanisms were discussed.  
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1. Introduction 
 
Acrylamide, an α,β-unsaturated reactive molecule [1], is widely used worldwide in industry. For 
example, it is used to synthesize polyacrylamide, a material that is frequently used in laboratories for 
gel electrophoresis experiments [2-4]. In daily life, acrylamide can be formed during the cooking and 
processing of foods via the decarboxylation of the Schiff base derived from carbonyl reactants, 
resulting in human consumption of relatively high doses of acrylamide [2-4]. The harmful effects of 
acrylamide have been proposed to be caused by its neurotoxicity [5-8], genotoxicity [9], 
carcinogenicity [10,11], reproductive and developmental toxicities [10] and cancer risk [11]. Among 
these toxic effects, epidemiological studies have shown that the neurotoxicity of acrylamide affects the 
nerve terminal functions. Acrylamide can modify the cysteine residues of presynaptic proteins, thereby 
significantly reducing the neurotransmitter release, which eventually leads to process degeneration 
[7,12]. Particularly, creatine kinase has been found to be significantly inhibited by acrylamide in the 
brain or sciatic nerve according to both in vitro and in vivo studies [13-15].  
Creatine kinase (CK, EC 2.7.3.2), a member of the phosphagen kinase family, catalyzes the 
reversible phosphotransfer between the ATP/ADP and Cr/PCr systems [16]. CK is highly expressed in 
vertebrate excitable tissues that require large energy fluxes and plays a crucial role in intracellular 
energetics [20-22]. There are four major CK isoforms, which are named according to their tissue 
distribution or subcellular localization [17]. Two tissue-specific (muscle or brain) cytosolic CKs exist 
as homo- (MM and BB) or hetero-dimers (MB) composed of muscle (M) or brain (B) monomers, 
while two mitochondria isoenzymes can exist as dimer or octamer [18]. CKs share a high similarity in 
their primary sequences and core structures (Figure 1) [19,20], while the minor difference may 
correlate to their isoenzyme-specific functions [21]. The ubiquitous brain-type BB-CK is widely 
distributed in brain, heart, smooth muscle, nervous system and other tissues, whereas the muscle-type 
CK (MM-CK) is the predominant isoform in highly differentiated skeletal muscle tissue [18,22]. Due 
to its crucial role in vertebrate energy metabolism, BB-CK is involved in many vital physiological 
processes and serious diseases [22-29]. CK has also long been used as a model enzyme, and its 
catalytic mechanism, structure, stability and folding has been extensively studied [19]. 
Figure 1. Structure of HBCK monomer (PDB ID: 3B6R) [20]. N and C denote the N- and 
C-terminus of the protein. The positions of the substrates are highlighted by the stick 
model. 
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Although BB-CK has been shown to be one of the targets of acrylamide [13,14], the underlying 
molecular mechanism is still unclear. Previous studies suggested that acrylamide can inhibit rabbit 
MM-CK (RMCK) and BB-CK (RBCK) by modifying the thiol groups of cysteines [15,30]. It is worth 
noting that BB-CK, but not MM-CK, is the predominant CK isoform in the brain and nervous system. 
Moreover, previous studies have identified the isoenzyme-specific functions and stability in CKs 
[21,31-33]. Thus it is worthwhile to investigate the effects of acrylamide on human BB-CK (HBCK) 
activity and structure. In this research, we investigated the effect of acrylamide on HBCK by activity 
assay, spectroscopic techniques and molecular simulation studies. The results herein are expected to 
further our understanding of the molecular mechanism of the toxic effects of acrylamide under 
physiological conditions. 
 
2. Results and Discussion 
 
2.1. Inactivation of HBCK by Acrylamide 
 
The effects of acrylamide on HBCK activity was evaluated by measuring the residual activity after 
incubation of the enzyme with various concentrations of acrylamide for 2 h. The data in Figure 2 
clearly indicate that HBCK was inactivated by acrylamide in a dose-dependent manner. The catalytic 
activity of HBCK was completely eliminated by ~300 mM acrylamide, and the IC50 value was   
~50 mM. It is worth noting that HBCK was much more easily to be inactivated by acrylamide than 
CKs from rabbit (RMCK and RBCK), which could still maintain about 10% of its activity at an 
acrylamide concentration of 600 mM and had an IC50 value of ~200 mM [15]. Although it is not clear 
whether acrylamide is harmful to rabbit CKs, the results herein strongly suggested that the human BB-
CK was much more sensitive to acrylamide-induced inactivation than CKs from rabbit. 
Figure 2. Effect of acrylamide on the activity of HBCK. The residual activity was 
measured after 2 h incubation of HBCK in 50 mM Tris-HCl buffer, pH 8.0, with the 
addition of various concentrations of acrylamide at 25 °C. The final enzyme concentration 
was 2 μM. The data are presented as average ± standard errors for three repetitions. 
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The inactivation kinetics were measured by time-course inactivation studies in the presence of 
various concentrations of acrylamide, and the results are presented in Figure 3. The time-dependent 
decrease of the enzyme activity of HBCK was best-fitted to a biphasic process, and the fast- (k1) and 
slow-phase (k2) rate constants are presented in Table 1. The changes in the transition free-energy 
(ΔΔG°') were also calculated by Equation 1 as described previously [30]: 
ΔΔG°' = –RTlnk' (1) 
where k' is a time constant for the major phase (fast phase) of the inactivation reaction, T is the 
absolute temperature, and R is the Boltzmann constant. These results indicated that neither the 
inactivation rate constants nor ΔΔG°' were significantly affected by the different concentrations of 
acrylamide, and the values were at the same order of magnitude.  
Figure 3. Inactivation kinetics of HBCK by various concentrations of acrylamide ranging 
from 0 to 800 mM. The enzyme solutions were mixed with various concentrations of 
acrylamide, and aliquots were taken at the indicated time points. Then the residual activity 
was measured using the standard activity assay, and the data were normalized by taking the 
activity recorded at 0 min as 100%. The data were fitted by a biphasic process, and the 
fitted data are presented as solid lines. The rate constants are presented in Table 1. 
 
Both RBCK and HBCK exhibited a biphasic process during acrylamide-induced inactivation, but 
they had different rate constants [30]. However, only a monophasic inactivation process was 
discovered for RMCK [15]. The difference might be caused by the relatively shorter time used for the 
study of RMCK or dissimilar inactivation mechanisms of the two isoenzymes by acrylamide. A 
comparison of the inactivation rate constants of HBCK/RBCK and RMCK indicated that although 
significant deviation was found for the fast phase rate constants, the slow phase rate constants of 
HBCK inactivation by acrylamide was almost identical for the three enzymes. It has been proposed 
that the inactivation of RBCK and RMCK by acrylamide was due to thiol depletion [15,30]. Because 
all CKs share a similar three-dimensional structure and the modification of thiol groups by acrylamide 
has the same rate constant, it is safe to conclude that the slow phase of HBCK inactivation was due to 
thiol depletion. This deduction was also supported by the fact that the rate constants of inactivation and Int. J. Mol. Sci. 2009, 10                 
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thiol depletion were at the same level [15,30]. The fast phase inactivation of the two BB-CKs might be 
due to specific binding of the acrylamide molecules to the enzyme. The comparison of the inactivation 
processes of the three enzymes also suggested that the inactivation efficiency of acrylamide was 
isoenzyme- and species-dependent. 
 
Table 1. Inactivation rate constants of HBCK in the presence of acrylamide. 
Acrylamide 
(mM) 
Inactivation rate constants (10
-3 s
-1) 
ΔΔG°' (kJ/mol·min
-1) 
k1  k2 
50 2.0  0.31  25.5 
100 2.9  0.21  24.6 
200 5.7  0.39  22.9 
400 3.5  0.65  24.1 
800 3.6  0.68  24.0 
 
2.2. Effect of Acrylamide on the Tertiary Structure of HBCK 
 
To elucidate the structural changes of HBCK by acrylamide, ANS extrinsic fluorescence was 
measured to probe the tertiary structural changes of HBCK induced by the addition of acrylamide. 
ANS has long been used as an extrinsic fluorescence probe to monitor the hydrophobic exposure of 
proteins [34]. As presented in Figure 4, the native HBCK exhibits typical ANS fluorescence emission 
maximum at around 470 nm, suggesting that, like MMCK [26,35-37], native BBCK molecules also 
contain ANS-binding sites.  
In the presence of acrylamide, the intensity of ANS emission fluorescence increased slightly (~20%) 
in an acrylamide concentration-dependent manner (inset of Figure 4), implying that the addition of 
acrylamide had a minor effect on the hydrophobic exposure of HBCK. At acrylamide concentrations 
above 256 mM, the ANS fluorescence had a significant blue-shift, accompanied by a decrease in 
intensity (data not shown), suggesting that high concentrations of acrylamide might interfere with the 
ANS fluorescence measurements.  
It is worth noting that the tertiary structural changes of HBCK were different from those of RBCK, 
although they are highly homogenous in their primary sequences. Our previous study has shown that 
no significant change was observed at acrylamide concentrations below 800 mM for RBCK [30]. 
Their dissimilar structural stability coincided with their different response to acrylamide-induced 
inactivation.  
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Figure 4. Effect of acrylamide on the ANS fluorescence of HBCK. The enzyme solutions 
were mixed with various concentrations of acrylamide and equilibrated for 2 h. The final 
concentration of ANS was 40 μM, and the solutions were incubated at ambient temperature 
for 30 min in the dark before measurements. The final enzyme concentration was 2 μM. 
The presented spectra were obtained by subtracting the spectra of ANS in the same buffer. 
 
 
Native-PAGE analysis was also performed to probe the change in the shape of the molecule   
(Figure 5), and the results were similar to those for RMCK and RBCK [15,30]. The shift of the band at 
acrylamide concentrations below 400 mM indicated that the tertiary structure of HBCK was modified 
by acrylamide, while the quaternary structure was not. The splitting of the band at acrylamide 
concentrations above 400 mM suggested that the thiol groups was alkylated by acrylamide, as 
proposed previously [30]. 
 
Figure 5. Native-PAGE analysis of the tertiary structural changes of HBCK induced by 
acrylamide. The protein was dissolved in 50 mM Tris-HCl buffer, pH 8.0, in the presence 
of various concentrations of acrylamide. Lanes 1-6 indicate the protein incubated in the 
buffer with the addition of 0, 50, 100, 200, 400 and 800 mM acrylamide, respectively. 
 
 
2.3. Acrylamide Binding-Site on HBCK by Docking Simulation 
 
The above results from inactivation and structural studies suggested that acrylamide might have 
specific binding sites on HBCK. Actually, a previous study suggested that the acrylamide binding-site 
at RBCK was at a pocket around Cys74 according to docking simulation of a predicted RBCK 
structure [30]. Recently, the crystal structures of HBCK in ligand-free and ligand-binding forms have Int. J. Mol. Sci. 2009, 10                 
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been published [20], and the results provided reliable structures for docking simulation studies. As 
presented in Figure 1, each subunit of CK contains two domains: a smaller N-terminal domain and a 
larger C-terminal domain, and the active site of CK is located at the cleft of the two domains [19]. This 
cleft or pocket is thought to facilitate the entry of substrates as well as inhibitors [19,30]. The HBCK 
pocket, which is estimated to be as large as ~2,500 Å
2, is shown in Figures 6A and 6B.  
 
Figure 6. The surface of HBCK (A and B) and acrylamide binding sites predicted by 
Autodock (C and D) and Fred (E and F). (A and B) The surface of the HBCK molecule. 
The yellow parts indicated the position of the cleft or pocket between the two domains of 
HBCK. Panel (B) shows the top view of the structure shown in panel (A). (C-F) The 
residues forming the binding site are shown by a line model, the acrylamide molecule is 
presented by a space-filling model, while Glu232 is highlighted by a stick model. 
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Three HBCK structures have been reported: the ligand-free (PDB ID: 3DRE), ADP-binding (PDB 
ID: 3DRB) and TSAC-binding (PDB ID: 3B6R) forms. To ensure the reliability of the docking results, 
all the crystal structures were used for the docking simulations, and no significant difference in the 
binding sites were found for the three crystal structures. The docking was also performed by both 
Autodock 4.0 and Fred 2.0 software programs, and the docking of the acrylamide molecule to the 
HBCK molecule was successful as indicated by the statistically significant scores (about -3.7 kcal/mol 
for Autodock and about -30 kcal/mol for Fred 2.0). Furthermore, we also tested the reliability by 
docking ADP to the ligand-free HBCK molecule, and the RMSD was 0.214 Å, which confirmed that 
the docking results were reliable. 
Surprisingly, the two programs give different sites of acrylamide-binding (Figure 6). Considering 
that the weak binding of acrylamide and different CK isoforms had dissimilar IC50 values, it is possible 
that CK contains multiple acrylamide binding sites. Moreover, the biphasic inactivation process also 
suggested that BB-CK might have acryamide binding sites with distinct binding affinities. This could 
also explain why different sites were predicted by the two programs and why different sites were 
predicted for the two highly homologous BB-CK enzymes. 
The binding site predicted by Autodock was formed by residues Pro143, Cys146, Arg151, Met207, 
Ala208, Arg209, Arg215,  Asn230, Glu231, Glu232, Asp233 and His234, while that by Fred was 
formed by residues Thr133, Gly134, Arg135, Glu232, Asp233, Leu235, Arg236, Leu281, Asn286 and 
Gly 290. These two potential acrylamide binding sites were adjacent, and two residues (Glu232 and 
Asp233) were predicted to participate in acrylamide binding for both cases. Previous structural and 
mutational studies have pointed out that Glu232 is one of the crucial residues responsible for CK 
catalysis by participating in the positioning of creatine (Figure 1) [19,20,30]. Thus the binding of 
acrylamide might impair the structure and flexibility of the active site by altering the position of 
Glu232, resulting in HBCK inactivation.  
A comparison of the results obtained herein and those of RMCK and RBCK [15,30] strongly 
suggested that the inhibition effect of acrylamide on CK might be isoenzyme- and species-specific. 
The structure and sequence are highly conserved among all CKs [19], and the identity in the primary 
sequence is 96.6% between HBCK and RBCK, and 80.1% between HBCK and RMCK. For all CKs, 
there is a large pocket between the N- and C-terminal domains to facilitate the entry of the substrates. 
Both the docking simulations in this research and that for RBCK suggested that the acrylamide binding 
sites were located at this pocket, but at different positions. These observations implied that acrylamide 
might have multi-binding sites on CK, while the affinity and position might influenced the structure of 
the active site in different ways. The disruption of the active site conformation might allow the 
modification of the thiol group of Cys283, a fully conserved residue crucial for CK, and further 
inactivate the enzyme. This proposal is consistent with the distinct IC50 values observed for the three 
CK isoenzymes, and could very well explain why different acrylamide binding sites were obtained for 
HBCK and RBCK by the two simulation programs. The species- and isoenzyme-specific response of 
CK against acrylamide-induced inactivation also suggested that great caution should be taken when 
using model proteins from other species to evaluate the effects of toxicants on human beings. 
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3. Experimental Section 
 
3.1. Materials and Protein Expression and Purification 
 
Creatine, ATP, DTT, magnesium acetate, thymol blue, acrylamide, and ANS were all purchased 
from Sigma. All the other reagents were local products of analytical grade. Recombinant HBCK was 
expressed and purified as described previously [30,37]. HBCK purity was confirmed by the presence 
of only one band in both SDS- and native-PAGE analyses, as well as LC-MS/MS identification. The 
protein concentration was determined according to the Bradford method by using bovine serum 
albumin as a standard [38]. 
 
3.2. HBCK Activity Assay 
 
HBCK activity was measured according to the pH-colorimetry method by following the proton 
generation during the reaction of ATP and creatine [39]. The enzymatic activity was monitored by the 
absorption at 597 nm with an Ultraspec 4300 pro UV/Visible spectrophotometer (Amersham 
Pharmacia Biotech), and the indicator was thymol blue. The reaction and measurements were 
performed at 25 °C. The assay buffer contained 24 mM creatine, 4 mM ATP, 8 mM magnesium 
acetate, 0.01% thymol blue, and 5 mM glycine-NaOH (pH 9.0).  
 
3.3. ANS Fluorescence 
 
The extrinsic fluorescence emission spectra were collected using a Hitachi F-2500 
spectrofluorimeter (Tokyo, Japan) using 1-cm-pathlength cuvettes. The protein solutions with various 
amounts of acrylamide were incubated with 40 μM ANS for 30 min in the dark. An excitation 
wavelength of 390 nm was used for ANS-binding fluorescence, and the emission wavelength ranged 
from 400 to 600 nm. 
 
3.4. In silico Docking of HBCK and Acrylamide 
 
To ensure the reliability of the docking results, all of the three published HBCK crystal structures 
(PDB IDs: 3DRE, 3DRB and 3B6R) [20] were used for the in silico docking simulations. Two 
programs, Autodock 4.0 and Fred 2.0, which are based on different search techniques, were used in 
this research [40,41]. The original structure of acrylamide was obtained from the PubChem database 
(http://www.pubchem.org; compound ID: 6579) [42]. Details regarding the procedures of docking 
simulations were the same as those described previously [30,43]. The reliability of the simulations was 
also examined by docking the ADP molecule to the ligand-free HBCK molecule, and the RMSD was 
0.214 Å, which confirmed that the docking results were reliable. 
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4. Conclusions 
 
Acrylamide, which is widely used worldwide in industry and can be produced by the cooking and 
processing of foods, has been found to be harmful to human beings. BB-CK has been proposed to be 
one of the important targets in the neurotoxicity of acrylamide. In this research, we studied the effects 
of acrylamide on human BB-CK activity, structure and the potential binding sites. Compared to CKs 
from rabbit, HBCK was fully inhibited at several-fold lower concentrations of acrylamide, and 
exhibited distinct properties upon acrylamide-induced inactivation and structural changes. The highly 
conserved structure of CKs but quite dissimilar responses suggested that the effects of acrylamide 
might be isoenzyme- and species-specific. The binding sites of acrylamide were proposed to be located 
at the cleft between the N- and C-terminal domains of CK, and the affinities of the multiple sites might 
be accounted for the slight difference in the sequence and structure of various CKs. This might be the 
structural basis of the different effect of acrylamide on various CKs. The results herein provide insight 
into the inhibitory effects and the possible ligand-binding mechanism of acrylamide on CK. 
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